1. Safety and Cross-Variant Immunogenicity of a Three-Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients
- Author
-
Antoine Sicard, Cecil Czerkinsky, Nicolas Glaichenhaus, Alexandre Gérard, Vincent L.M. Esnault, Matthieu Rouleau, Emanuela Martinuzzi, Marion Cremoni, Ghislaine Bernard, Nadia Ben Hassen, Lory Rogier, Susana Barbosa, Filippo Massa, Barbara Seitz-Polski, Hanen Grabsi, Guillaume Favre, Mathilde Blois, Paul Hofman, and Julien Fayada
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Immunogenicity ,Vaccination ,Titer ,Regimen ,Tolerability ,Internal medicine ,biology.protein ,Medicine ,Seroconversion ,Antibody ,business ,Neutralizing antibody - Abstract
Background: The immunogenicity of a two-dose mRNA COVID-19 vaccine regimen is low in kidney transplant (KT) recipients. We report the first complete assessment of safety and cross-variant immunogenicity of a three-dose vaccine regimen in KT recipients. Methods: We performed a prospective longitudinal study in sixty-one KT recipients given three doses of the BNT162b2 COVID-19 vaccine. We performed semi-structured pharmacovigilance interviews and monitored donor-specific antibodies and kidney function. We compared geometric mean titers (GMT) of anti-spike IgG, pseudo-neutralization activity against vaccine homologous and heterologous variants, frequency of spike-specific interferon (IFN)-γ-secreting cells, and antigen-induced cytokine production 28 days after the second and third doses. The immunoassays were also performed in non-transplanted individuals 28 days after the second dose to obtain reference values. Findings: Reactions to vaccine were mild. One patient developed donor-specific anti-HLA antibodies after the second dose which could be explained by non-adherence to immunosuppressive therapy. Spike-specific IgG seroconversion raised from 44·3% (n=27) after the second dose to 62·3% (n=38) after the third dose (p
- Published
- 2021
- Full Text
- View/download PDF